Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma | Zendy

Antoni Ribas | Zendy; Omid Hamid | Zendy; Adil Daud | Zendy; F. Stephen Hodi | Zendy; Jedd D. Wolchok | Zendy; Richard Kefford | Zendy; Anthony M. Joshua | Zendy; Amita Patnaik | Zendy; Wen-Jen Hwu | Zendy; Jeffrey S. Weber | Zendy; Tara C. Gangadhar | Zendy; Peter Hersey | Zendy; Roxana Dronca | Zendy; Richard W. Joseph | Zendy; Hassane M. Zarour | Zendy; Bartosz Chmielowski | Zendy; Donald P. Lawrence | Zendy; Alain P. Algazi | Zendy; Naiyer A. Rizvi | Zendy; Brianna Hoffner | Zendy; Christine Mateus | Zendy; Kevin Gergich | Zendy; Jill A. Lindia | Zendy; Maxine Giannotti | Zendy; Xiaoyun Li | Zendy; Scot Ebbinghaus | Zendy; Soonmo Peter Kang | Zendy; Caroline Robert | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma

Author(s) -

Antoni Ribas,

Omid Hamid,

Adil Daud,

F. Stephen Hodi,

Jedd D. Wolchok,

Richard Kefford,

Anthony M. Joshua,

Amita Patnaik,

Wen-Jen Hwu,

Jeffrey S. Weber,

Tara C. Gangadhar,

Peter Hersey,

Roxana Dronca,

Richard W. Joseph,

Hassane M. Zarour,

Bartosz Chmielowski,

Donald P. Lawrence,

Alain P. Algazi,

Naiyer A. Rizvi,

Brianna Hoffner,

Christine Mateus,

Kevin Gergich,

Jill A. Lindia,

Maxine Giannotti,

Xiaoyun Li,

Scot Ebbinghaus,

Soonmo Peter Kang,

Caroline Robert

Publication year - 2016

Publication title -

jama

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 4.688

H-Index - 680

eISSN - 1538-3598

pISSN - 0098-7484

DOI - 10.1001/jama.2016.4059

Subject(s) - medicine , ipilimumab , pembrolizumab , melanoma , oncology , clinical endpoint , clinical trial , cohort , immunotherapy , cancer , cancer research

The programmed death 1 (PD-1) pathway limits immune responses to melanoma and can be blocked with the humanized anti-PD-1 monoclonal antibody pembrolizumab.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research